Harmony Biosciences Reports Preliminary 2025 WAKIX Net Revenue of ~$868M, $243M In Q4; Sees 2026 Revenue Of $1B-$1.04B
Benzinga Newsdesk 9 months ago
NewsGuidance
WAKIX 2025 Preliminary Net Revenue of ~$868 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in NarcolepsyOn Track to Extend the Pitolisant Franchise into the 2040s With
WAKIX 2025 Preliminary Net Revenue of ~$868 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in Narcolepsy
On Track to Extend the Pitolisant Franchise into the 2040s With Next-Gen Pitolisant Formulations
Potential Best-In-Class Orexin-2 Agonist (BP1.15205) Phase 1 Trial Ongoing; Clinical Data Expected in Mid-2026
Robust Late-Stage Pipeline with Five Ongoing Phase 3 Registrational Clinical Trials in Five Distinct CNS Indications
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced strong preliminary, unaudited net product revenue for Q4 and full year 2025 of approximately $243 million and $868 million, respectively. The company continues to build on six consecutive years of revenue growth. On track to extend the pitolisant franchise, Harmony fortifies its profile as a profitable, self-funding biotech company with a robust, late-stage pipeline and strong long-term growth potential. Harmony will highlight its commercial performance and pipeline advancements at its presentation at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 4:30 p.m. PT / 7:30 p.m. ET in San Francisco, CA.